Patient characteristics, CTL infusions, and clinical status. WLE, wide local excision; LND, lymph node dissection; HD IL-2, high-dose IL-2; IFN, interferon-α; RT, radiation therapy; PD, progressive disease; SD, stable disease; CR, complete response; PR, partial response; MR, mixed response.
| No. | Age/sex | Metastatic disease at study entry | Previous therapy | Total cells infused | Status on day 70 | Time to next therapy | Outcome after CTL or next therapy | Duration of response (months) | |
| Graft 1 | Graft 2 | ||||||||
| 1 | 74/M | Liver, adrenal, spleen, lung, skin | LND; carboplatin, paclitaxel, sorafenib; gp100 vaccine | 4.0 × 108 | None | Death on day 51 | — | Died without therapy | — |
| 2 | 69/M | Lung, skin | WLE; LND; temozolomide; melphalan limb perfusion | 4.0 × 108 | 4.0 × 108 | PD | Day 103 ipilimumab (10 mg/kg) | PR | 16 |
| 3 | 49/F | Lung, adrenal | WLE; LND; RT; HD IL-2 | 4.3 × 108 | 4.3 × 108 | MR | Day 146 ipilimumab (10 mg/kg) | PR | 31+ |
| 4 | 68/M | Skeletal muscle, lung, mediastinum, cardiac | Small-bowel resection; HD IL-2; ipilimumab versus gp100 versus both | 3.8 × 108 | 3.8 × 108 | SD | Day 140 RAF265 | SD | 3 |
| 5 | 66/M | Lymph nodes | WLE; LND | 4.4 × 109 | 2.5 × 109 | PR | No other therapy | CR to CTL day 140 | 25+ |
| 6 | 55/M | Lung | WLE; LND; pulmonary nodule resection | 1.8 × 109 | 3.4 × 109 | SD | Day 287 HD IL-2 | Death due to line sepsis | — |
| 7 | 70/F | Lung, skin | WLE; LND; adjuvant IFN | 4.0 × 109 | 4.0 × 109 | PD | Day 335 ipilimumab (3 mg/kg) | SD | 6 |
| 8 | 80/M | Lung, mediastinum | LND; RT; temozolomide | 3.6 × 109 | 3.6 × 109 | SD | Day 372 ipilimumab (3 mg/kg) | SD | 5 |
| 9 | 64/M | Lung, skin | WLE; LND; adjuvant IFN | 4.4 × 109 | 4.4 × 109 | PD | Day 146 ipilimumab (10 mg/kg) + bevacizumab | PR | 13+ |